The FDA is working under a congressional mandate to adopt a more nimble approach to regulation of regenerative medicine, and the agency has responded with enforcement action against multiple clinics even as FDA Commissioner Scott Gottlieb announced that the agency will “advance a comprehensive policy framework” for regenerative medicine before the end of the calendar year.